Literature DB >> 23942916

Impact of age cutoffs on a lynch syndrome screening program.

James M Gudgeon1, Thomas W Belnap, Janet L Williams, Marc S Williams.   

Abstract

PURPOSE: To determine the impact of applying an age cutoff to tumor-based Lynch syndrome (LS) screening, specifically focusing on changes in relative effectiveness, efficiency, and cost. The project was undertaken to answer questions about implementation of the LS screening program in an integrated health care delivery system. PATIENTS AND METHODS: Clinical data extracted from an internal cancer registry, previous modeling efforts, published literature, and gray data were used to populate decision models designed to answer questions about the impact of age cutoffs in LS screening. Patients with colorectal cancer (CRC) were stratified at 10-year intervals from ages 50 to 80 years and compared with no age cutoff. Outcomes are reported for a cohort of 325 patients screened and includes total cost to screen, LS cases present in the cutoff category, number of LS cases expected to be identified by screening, cost per LS case detected, and total number and percentage of LS cases missed.
CONCLUSION: Applying an age cutoff to an LS screening program has considerable potential for decreasing total screening costs and increasing efficiency, but at a loss of effectiveness. Imposing an age cutoff of 50 years reduces the cost of the screening program to 16% of a program with no age cutoff, but at the expense of missing more than half of the cases. Failure to identify LS cases is magnified by a cascade effect in family members. The results of this analysis influenced the final policy in our system.

Entities:  

Mesh:

Year:  2012        PMID: 23942916      PMCID: PMC3710164          DOI: 10.1200/JOP.2012.000573

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  12 in total

1.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

2.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 3.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.

Authors:  Noralane M Lindor; Gloria M Petersen; Donald W Hadley; Anita Y Kinney; Susan Miesfeldt; Karen H Lu; Patrick Lynch; Wylie Burke; Nancy Press
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

4.  Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.

Authors:  Katarina Ohrling; David Edler; Marja Hallström; Peter Ragnhammar
Journal:  Acta Oncol       Date:  2010-08       Impact factor: 4.089

5.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

6.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Authors:  Monica M Bertagnolli; Donna Niedzwiecki; Carolyn C Compton; Hejin P Hahn; Margaret Hall; Beatrice Damas; Scott D Jewell; Robert J Mayer; Richard M Goldberg; Leonard B Saltz; Robert S Warren; Mark Redston
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

Review 7.  EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.

Authors:  Glenn E Palomaki; Monica R McClain; Stephanie Melillo; Heather L Hampel; Stephen N Thibodeau
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

8.  Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.

Authors:  Cecelia A Bellcross; Sara R Bedrosian; Elvan Daniels; Debra Duquette; Heather Hampel; Kory Jasperson; Djenaba A Joseph; Celia Kaye; Ira Lubin; Laurence J Meyer; Michele Reyes; Maren T Scheuner; Sheri D Schully; Leigha Senter; Sherri L Stewart; Jeanette St Pierre; Judith Westman; Paul Wise; Vincent W Yang; Muin J Khoury
Journal:  Genet Med       Date:  2011-10-27       Impact factor: 8.822

10.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Authors:  Mercy Mvundura; Scott D Grosse; Heather Hampel; Glenn E Palomaki
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  9 in total

1.  Tumor-based screening for hereditary nonpolyposis colorectal cancer: does age-based selection optimize yield?

Authors:  Patrick M Lynch
Journal:  J Oncol Pract       Date:  2013-04-02       Impact factor: 3.840

2.  Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Authors:  Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

3.  Applying public health screening criteria: how does universal newborn screening compare to universal tumor screening for Lynch syndrome in adults with colorectal cancer?

Authors:  Deborah Cragun; Rita D DeBate; Tuya Pal
Journal:  J Genet Couns       Date:  2014-10-18       Impact factor: 2.537

4.  When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-09-24

5.  Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.

Authors:  Celine H M Leenen; Anne Goverde; Esther W de Bekker-Grob; Anja Wagner; Margot G F van Lier; Manon C W Spaander; Marco J Bruno; Carli M Tops; Ans M W van den Ouweland; Hendrikus J Dubbink; Ernst J Kuipers; Winand N M Dinjens; Monique E van Leerdam; Ewout W Steyerberg
Journal:  Genet Med       Date:  2016-03-03       Impact factor: 8.822

6.  Implementing universal Lynch syndrome screening (IMPULSS): protocol for a multi-site study to identify strategies to implement, adapt, and sustain genomic medicine programs in different organizational contexts.

Authors:  Alanna Kulchak Rahm; Deborah Cragun; Jessica Ezzell Hunter; Mara M Epstein; Jan Lowery; Christine Y Lu; Pamala A Pawloski; Ravi N Sharaf; Su-Ying Liang; Andrea N Burnett-Hartman; James M Gudgeon; Jing Hao; Susan Snyder; Radhika Gogoi; Ilene Ladd; Marc S Williams
Journal:  BMC Health Serv Res       Date:  2018-10-30       Impact factor: 2.655

7.  Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.

Authors:  Dayna R Cenin; Steffie K Naber; Iris Lansdorp-Vogelaar; Mark A Jenkins; Daniel D Buchanan; David B Preen; Hooi C Ee; Peter O'Leary
Journal:  J Gastroenterol Hepatol       Date:  2018-05-17       Impact factor: 4.029

8.  Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer.

Authors:  Jing Hao; Dina Hassen; James M Gudgeon; Susan R Snyder; Heather Hampel; Marc S Williams; Ravi N Sharaf; Christine Y Lu; Janet L Williams; Victoria Schlieder; Alanna Kulchak Rahm
Journal:  J Pers Med       Date:  2021-12-02

9.  Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through.

Authors:  Deborah Cragun; Rita D DeBate; Susan T Vadaparampil; Julie Baldwin; Heather Hampel; Tuya Pal
Journal:  Genet Med       Date:  2014-03-20       Impact factor: 8.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.